TOKYO--(BUSINESS WIRE)--Jun 12, 2026--
Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company, today announced the successful dosing of the first patient in its domestic Phase I/II EMERALD study of HS-005, allogeneic iPS cell-derived cardiomyocyte spheroids administered via catheter, targeting severe heart failure caused by ischemic heart disease or dilated cardiomyopathy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611923545/en/
This study marks the world's first clinical trial to administer iPS cell-derived cardiomyocyte spheroids using a catheter. The administration to the first patient suffering from dilated cardiomyopathy was successfully completed at Shinshu University Hospital in late March 2026. The patient's postoperative course has been generally uneventful, and the patient has already been discharged. Furthermore, the independent Safety Monitoring Committee evaluated the 4-week data and approved the study to continue in dilated cardiomyopathy cohort.
"Catheter administration enables the minimally invasive delivery of cardiomyocytes", said Keiichi Fukuda, CEO of Heartseed. "The inclusion of patients with dilated cardiomyopathy as a new target is a highly significant milestone in our goal to save more patients with severe heart failure.”
About HS-005 and EMERALD Study
While Heartseed's lead pipeline, HS-001 requires open-heart surgery, HS-005 enables next-gen, minimally invasive cardiac regenerative medicine by endocardial catheter delivery. The administered cardiomyocytes are expected to engraft into the patient's myocardium, improving cardiac contractility by remuscularization and promoting neovascularization. The EMERALD study aims at treating severe heart failure with reduced ejection fraction (HFrEF) caused by ischemic heart disease or dilated cardiomyopathy. The study plans to enroll 7 patients in each cohort, for a total of 14 patients to evaluate the safety and efficacy of the therapy.
About Heart Failure
Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body’s needs. It affects more than 65 million people globally. Aside from heart transplantation, there are no radical treatment options, creating a strong demand for innovative therapies.
About Heartseed
Heartseed Inc. was founded in 2015 to realize cardiac remuscularization therapy, and it was listed on the Tokyo Stock Exchange Growth Market in July 2024 (Stock Code: 219A). Heartseed has proprietary technologies throughout the entire manufacturing process of the cardiomyocyte cell product, including iPSC production, purification, and cell delivery.
For more information, visit heartseed.jp, LinkedIn and YouTube.
For details: https://heartseed.jp/en/news.html
Cardiomyocyte spheroids
PHOENIX--(BUSINESS WIRE)--Jul 27, 2026--
Centuri Holdings, Inc. (NYSE: CTRI) (“Centuri” or the "Company"), a leading, North American utility and energy infrastructure services company, today released its 2025 Sustainability Report ( https://sustainability.centuri.com/ ), which details initiatives aligned to its recently released Vision One Centuri Strategy and progress against the Company’s 15 Key Performance Indicators (KPIs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727162968/en/
Centuri’s 2025 Sustainability Report highlights include:
“We are focused on sustainably scaling our business by investing in the people and processes that will strengthen our Company for the long-term. Our sustainability efforts emphasize strong governance and strategic activities that mitigate risk and ensure we can meet our diverse stakeholder expectations and customer needs for many years to come," said Centuri President and CEO Christian Brown. "Guided by our recently released Vision One Centuri Strategy, our team from the field to the highest leadership level is aligned on advancing key initiatives that allow us to sustainably grow and deliver on our stated objectives.”
The 2025 report details Centuri’s investment in its people, protocols, safety programs, and partnerships. Further highlights include, onboarding more than 1,000 employees, investing significantly in leadership development, strengthening stakeholder outreach through dedicated forums, launching a standardized pre-job safety brief, updating the Delegation of Authority from its board of directors to management to further improve corporate governance and disciplined risk management, completing a third-party risk assessment to enhance the maturity of the Company’s risk management approach, and establishing an AI Steering Committee to guide adoption and implementation of next-generation technologies.
In addition, the 2025 report includes the Company’s Sustainability Accounting Standards Board (SASB) disclosure as well as alignment to six UN Sustainable Development Goals.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can often be identified by the use of words such as “will,” “predict,” “continue,” “forecast,” “expect,” “believe,” “anticipate,” “outlook,” “could,” “target,” “project,” “intend,” “plan,” “seek,” “estimate,” “should,” “may” and “assume,” as well as variations of such words and similar expressions referring to the future. The specific forward-looking statements made herein include (without limitation) statements regarding the Company’s sustainability efforts emphasizing strong governance and strategic activities that mitigate risk and ensure the Company can meet its diverse stakeholder expectations and customer needs for many years to come; and the Company, under the guidance of its Vision One Centuri Strategy, is aligned internally on advancing key initiatives that allow it to sustainably grow and deliver on its stated objectives. A number of important risks, uncertainties and other factors affecting the business and financial results of Centuri could cause actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, capital market risks and the impact of general economic or industry conditions and those detailed from time to time in Centuri’s reports filed with the Securities and Exchange Commission (the “SEC”), including Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 28, 2025. Factors that could cause actual results to differ also include (without limitation) those discussed in Centuri’s filings filed from time to time with the SEC. The statements in this press release are (i) made as of the date of this press release, even if subsequently made available by Centuri on its website or otherwise, and (ii) based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Except to the extent required by applicable law, Centuri does not assume any obligation to update or revise the forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. You are cautioned not to place undue reliance on these forward-looking statements.
Centuri releases its 2025 Sustainability Report
